Aduhelm Approval Boosts Other Alzheimer’s Drug Developers
Even Companies Not Focused On Clearing Amyloid Benefitted
Biogen/Eisai’s aducanumab, as the first disease-modifying therapy and setting a precedent for accelerated approval, lifted the entire Alzheimer’s field.
You may also be interested in...
With 88 initial public offerings in the US through the end of the third quarter of 2021, the biopharma industry is two IPOs ahead of the full-year 2020 total, but with an average return of -4% momentum may slow.
After discussions with the US FDA, the company determined it can file AMX0035 based on Phase II/III results and interim Phase III data. Amylyx is sticking with its go-it-alone strategy for global commercialization.
Backed by investors such as Sofinnova, Polaris and Sanofi Ventures, Muna has assembled a strong team dedicated to developing small molecules to repair neuronal dysfunction and resolve neuroinflammation.